{
    "info": {
        "nct_id": "NCT03513952",
        "official_title": "A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma",
        "inclusion_criteria": "* Patients must have histologically or cytologically documented locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra\n\n  * Note: Mixed histology tumors allowed if predominant histology is urothelial carcinoma\n  * Note: Small cell or neuroendocrine carcinoma is not allowed if predominant\n* Patients must have recurrent disease after any prior platinum-based chemotherapy regimen\n* Patients must have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)\n* ECOG performance status =< 2 (Karnofsky >= 60%)\n* Patients must have a life expectancy of greater or equal to 12 weeks\n* Leukocytes >= 2,500/mcL\n* Absolute neutrophil count >= 1,000/mcL\n* Platelets >= 100,000/mcL\n* Hemoglobin >= 8 g/dL\n* Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert's disease who have serum bilirubin level =< 3 x ULN may be enrolled)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (AST and/or ALT=< 5 x ULN for patients with liver involvement)\n* Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)\n* Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault\n\n  * At the discretion of the treating physician, a 24-hour urine creatinine clearance could be obtained and utilized as the gold standard if creatinine clearance by Cockcroft-Gault is < 30, and prevents patient enrollment on the trial\n* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)\n* Patients must provide tissue from an archival tumor sample (obtained within 2 years from screening visit) or newly obtained core, punch, or excisional biopsy of a tumor lesion if deemed relatively safe and technically feasible\n* Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of study agent(s); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;\n\n  * Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; CYT107 has not been tested for reproductive toxicity yet and may expose to the same risk; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n* Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active antiretroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatment\n* Patients who have received more than 2 systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma\n\n  * Note: Prior perioperative chemotherapy is allowed and is not counted as a line of therapy if patient relapsed >= 12 months later and received additional platinum-based chemotherapy for metastatic disease\n* Patients who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier (i.e., have residual toxicities > grade 1); however, the following therapies are allowed:\n\n  * Hormone-replacement therapy or oral contraceptives\n  * Herbal therapy >= 1 week before initiation of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least 1 week before initiation of study treatment)\n  * Palliative radiotherapy for bone metastases > 2 weeks before initiation of study treatment\n* Patients who have received prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway -targeting agents\n\n  * Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\n\n    * Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\n    * No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)\n* Patients who have received treatment with any other investigational agent within 4 weeks before initiation of study treatment\n* Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of study treatment\n* Patients who have received treatment with systemic immunosuppressive medications (including, but not limited to, oral prednisone ( > 10 mg/day or equivalent), cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti TNF] agents) within 2 weeks before initiation of study treatment\n\n  * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled\n  * The use of inhaled corticosteroids, and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\n* Patients taking bisphosphonate therapy for symptomatic hypercalcemia\n\n  * Note: Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed\n* Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions:\n\n  * Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:\n\n    * Evaluable or measurable disease outside the CNS\n    * No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)\n    * No history of intracranial hemorrhage or spinal cord hemorrhage\n    * No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted\n    * No neurosurgical resection or brain biopsy within 28 days before initiation of study treatment\n  * Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:\n\n    * Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study\n    * No stereotactic radiation or whole-brain radiation within 28 days before initiation of study treatment\n    * Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids\n  * Note: Patients with CNS metastases enrolled on trial must also have a brain MRI imaging at all standard radiologic evaluation timepoints\n* Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies\n* Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* Patients with known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver/nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH); and inherited liver disease\n\n  * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)\n* Patients with active underlying autoimmune disease requiring systemic immunosuppressive medication (oral prednisone > 10 mg/day or equivalent). Topical, inhaled, or intra-articular steroids or physiologic endocrine replacement (insulin, levothyroxine, etc.) are permitted. Patients with a history of autoimmune disease that is not currently active require consultation with the protocol principal investigator (PI) and/or Cancer Immunotherapy Trials Network (CITN) Coordinating Center\n* Patients who have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Patients who have known additional malignancies other than UBC within 2 years before initiation of study treatment; exceptions include malignancies with a negligible risk of metastasis or death and treated with expected curative outcome (e.g., non-melanomatous skin cancers), or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer\n* Patients with active tuberculosis (TB)\n* Patients who have leptomeningeal disease\n* Patients who have severe infections within 4 weeks before initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia;\n\n  * Exception: Uncomplicated urinary tract infection will not be considered as a severe infection in these patients\n* Patients who have signs or symptoms of infection within 2 weeks before initiation of study treatment\n* Patients who have received oral or IV antibiotics within 2 weeks before initiation of study treatment; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible\n* Patients who have major surgical procedure, other than for diagnosis, within 28 days before initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study\n* Patients who have had a live, attenuated vaccine within 4 weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab.\n\n  * Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks before initiation of study treatment or at any time during the study\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction (within the last 6 months), or psychiatric illness/social situations that would limit compliance with study requirements\n* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g., infectious) illness",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
            "criterions": [
                {
                    "exact_snippets": "No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                    "criterion": "concurrent antibiotics or antifungal agents for prevention of opportunistic infections",
                    "requirements": [
                        {
                            "requirement_type": "requirement for use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)",
            "criterions": [
                {
                    "exact_snippets": "Patients must have measurable disease per RECIST 1.1",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)",
                    "criterion": "disease assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computed tomography (CT) scan",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:",
            "criterions": [
                {
                    "exact_snippets": "Patients positive for human immunodeficiency virus (HIV)",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have recurrent disease after any prior platinum-based chemotherapy regimen",
            "criterions": [
                {
                    "exact_snippets": "Patients must have recurrent disease",
                    "criterion": "recurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after any prior platinum-based chemotherapy regimen",
                    "criterion": "prior platinum-based chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Small cell or neuroendocrine carcinoma is not allowed if predominant",
            "criterions": [
                {
                    "exact_snippets": "Small cell or neuroendocrine carcinoma is not allowed if predominant",
                    "criterion": "histology (small cell or neuroendocrine carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "predominance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must provide tissue from an archival tumor sample (obtained within 2 years from screening visit) or newly obtained core, punch, or excisional biopsy of a tumor lesion if deemed relatively safe and technically feasible",
            "criterions": [
                {
                    "exact_snippets": "Patients must provide tissue from an archival tumor sample (obtained within 2 years from screening visit)",
                    "criterion": "archival tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "age of sample",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "newly obtained core, punch, or excisional biopsy of a tumor lesion if deemed relatively safe and technically feasible",
                    "criterion": "newly obtained tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "type of biopsy",
                            "expected_value": [
                                "core",
                                "punch",
                                "excisional"
                            ]
                        },
                        {
                            "requirement_type": "safety and technical feasibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leukocytes >= 2,500/mcL",
            "criterions": [
                {
                    "exact_snippets": "Leukocytes >= 2,500/mcL",
                    "criterion": "leukocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2500,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 8 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,000/mcL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert's disease who have serum bilirubin level =< 3 x ULN may be enrolled)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert's disease who have serum bilirubin level =< 3 x ULN may be enrolled",
                    "criterion": "serum bilirubin in patients with known Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At the discretion of the treating physician, a 24-hour urine creatinine clearance could be obtained and utilized as the gold standard if creatinine clearance by Cockcroft-Gault is < 30, and prevents patient enrollment on the trial",
            "criterions": [
                {
                    "exact_snippets": "creatinine clearance by Cockcroft-Gault is < 30",
                    "criterion": "creatinine clearance by Cockcroft-Gault",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "24-hour urine creatinine clearance could be obtained and utilized as the gold standard if creatinine clearance by Cockcroft-Gault is < 30",
                    "criterion": "24-hour urine creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status =< 2 (Karnofsky >= 60%)",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky >= 60%",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; CYT107 has not been tested for reproductive toxicity yet and may expose to the same risk; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",
            "criterions": [
                {
                    "exact_snippets": "women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "before study entry, for the duration of study participation, and for 5 months (150 days) after the last dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of child-bearing potential",
                    "criterion": "child-bearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child-bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men must agree to use adequate contraception",
                    "criterion": "sex (male)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have the ability to understand and the willingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have histologically or cytologically documented locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically documented",
                    "criterion": "urothelial bladder carcinoma documentation",
                    "requirements": [
                        {
                            "requirement_type": "documentation_method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC)",
                    "criterion": "urothelial bladder carcinoma stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "inoperable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra",
                    "criterion": "urothelial bladder carcinoma primary site",
                    "requirements": [
                        {
                            "requirement_type": "primary_site",
                            "expected_value": [
                                "renal pelvis",
                                "ureters",
                                "urinary bladder",
                                "urethra"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ... =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "only to patients who do not receive therapeutic anticoagulation"
                        }
                    ]
                },
                {
                    "exact_snippets": "activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "only to patients who do not receive therapeutic anticoagulation"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose",
                    "criterion": "therapeutic anticoagulation dose stability",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Mixed histology tumors allowed if predominant histology is urothelial carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Mixed histology tumors allowed if predominant histology is urothelial carcinoma",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "predominant histology",
                            "expected_value": "urothelial carcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m^2"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a life expectancy of greater or equal to 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of greater or equal to 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A stable regimen of highly active antiretroviral therapy (HAART)",
            "criterions": [
                {
                    "exact_snippets": "A stable regimen of highly active antiretroviral therapy (HAART)",
                    "criterion": "highly active antiretroviral therapy (HAART) regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of study agent(s); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of study agent(s)",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine",
                                "serum"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours before first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase =< 2.5 x ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(=< 5 x ULN for patients with documented liver involvement or bone metastases)",
                    "criterion": "alkaline phosphatase (in patients with documented liver involvement or bone metastases)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests",
            "criterions": [
                {
                    "exact_snippets": "CD4 count above 250 cells/mcL",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "cells/mcL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "test_method",
                            "expected_value": "standard polymerase chain reaction (PCR)-based tests"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/mcL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "per mcL"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",
            "criterions": [
                {
                    "exact_snippets": "known hypersensitivity to Chinese hamster ovary cell products",
                    "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... other recombinant human antibodies",
                    "criterion": "hypersensitivity to recombinant human antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have severe infections within 4 weeks before initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia;",
            "criterions": [
                {
                    "exact_snippets": "severe infections within 4 weeks before initiation of study treatment",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "time since occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of study treatment",
                    "criterion": "treatment with systemic immunostimulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks before initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exception: Uncomplicated urinary tract infection will not be considered as a severe infection in these patients",
            "criterions": [
                {
                    "exact_snippets": "severe infection ... Uncomplicated urinary tract infection will not be considered as a severe infection",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Patients who have leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:",
            "criterions": [
                {
                    "exact_snippets": "asymptomatic untreated CNS disease",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received prior treatment with anti-CTLA-4",
                    "criterion": "prior treatment with anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver/nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH); and inherited liver disease",
            "criterions": [
                {
                    "exact_snippets": "known clinically significant liver disease",
                    "criterion": "clinically significant liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active viral ... hepatitis",
                    "criterion": "active viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "alcoholic ... hepatitis",
                    "criterion": "alcoholic hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other hepatitis",
                    "criterion": "other hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "fatty liver/nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH)",
                    "criterion": "fatty liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "inherited liver disease",
                    "criterion": "inherited liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received treatment with systemic immunosuppressive medications (including, but not limited to, oral prednisone ( > 10 mg/day or equivalent), cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti TNF] agents) within 2 weeks before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "received treatment with systemic immunosuppressive medications (including, but not limited to, oral prednisone ( > 10 mg/day or equivalent), cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti TNF] agents) within 2 weeks before initiation of study treatment",
                    "criterion": "treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "medication_type",
                            "expected_value": [
                                "oral prednisone",
                                "cyclophosphamide",
                                "azathioprine",
                                "methotrexate",
                                "thalidomide",
                                "anti-tumor necrosis factor agents"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "route",
                            "expected_value": "systemic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Patients with CNS metastases enrolled on trial must also have a brain MRI imaging at all standard radiologic evaluation timepoints",
            "criterions": [
                {
                    "exact_snippets": "Patients with CNS metastases ... must also have a brain MRI imaging at all standard radiologic evaluation timepoints",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must also have a brain MRI imaging at all standard radiologic evaluation timepoints",
                    "criterion": "brain MRI imaging at all standard radiologic evaluation timepoints",
                    "requirements": [
                        {
                            "requirement_type": "requirement for imaging",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No stereotactic radiation or whole-brain radiation within 28 days before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "No stereotactic radiation ... within 28 days before initiation of study treatment",
                    "criterion": "stereotactic radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No ... whole-brain radiation within 28 days before initiation of study treatment",
                    "criterion": "whole-brain radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids",
            "criterions": [
                {
                    "exact_snippets": "Screening CNS radiographic study >= 4 weeks from completion of radiotherapy",
                    "criterion": "screening CNS radiographic study",
                    "requirements": [
                        {
                            "requirement_type": "timing from completion of radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Screening CNS radiographic study ... >= 2 weeks from discontinuation of corticosteroids",
                    "criterion": "screening CNS radiographic study",
                    "requirements": [
                        {
                            "requirement_type": "timing from discontinuation of corticosteroids",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients taking bisphosphonate therapy for symptomatic hypercalcemia",
            "criterions": [
                {
                    "exact_snippets": "Patients taking bisphosphonate therapy",
                    "criterion": "bisphosphonate therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for symptomatic hypercalcemia",
                    "criterion": "symptomatic hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Herbal therapy >= 1 week before initiation of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least 1 week before initiation of study treatment)",
            "criterions": [
                {
                    "exact_snippets": "Herbal therapy >= 1 week before initiation of study treatment",
                    "criterion": "herbal therapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_time_before_study",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "herbal therapy intended as anticancer therapy must be discontinued at least 1 week before initiation of study treatment",
                    "criterion": "herbal therapy intended as anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_time_before_study",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have had a live, attenuated vaccine within 4 weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab.",
            "criterions": [
                {
                    "exact_snippets": "had a live, attenuated vaccine within 4 weeks before initiation of study treatment",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before study treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated administration period",
                            "expected_value": [
                                "during the study",
                                "up to 5 months after the last dose of atezolizumab"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
            "criterions": [
                {
                    "exact_snippets": "history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Palliative radiotherapy for bone metastases > 2 weeks before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Palliative radiotherapy for bone metastases > 2 weeks before initiation of study treatment",
                    "criterion": "palliative radiotherapy for bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "timing before initiation of study treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received more than 2 systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma",
            "criterions": [
                {
                    "exact_snippets": "received more than 2 systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma",
                    "criterion": "number of systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible",
            "criterions": [
                {
                    "exact_snippets": "negative hepatitis B surface antigen [HBsAg] test",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive anti-HBc [antibody to hepatitis B core antigen] antibody test",
                    "criterion": "anti-HBc (antibody to hepatitis B core antigen) antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)",
            "criterions": [
                {
                    "exact_snippets": "No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)",
                    "criterion": "immune-related adverse effects from anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "CTCAE grade"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "CTCAE grade"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No history of intracranial hemorrhage or spinal cord hemorrhage",
            "criterions": [
                {
                    "exact_snippets": "No history of intracranial hemorrhage",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No history of ... spinal cord hemorrhage",
                    "criterion": "spinal cord hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No neurosurgical resection or brain biopsy within 28 days before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "No neurosurgical resection ... within 28 days before initiation of study treatment",
                    "criterion": "neurosurgical resection",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No ... brain biopsy within 28 days before initiation of study treatment",
                    "criterion": "brain biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active underlying autoimmune disease requiring systemic immunosuppressive medication (oral prednisone > 10 mg/day or equivalent). Topical, inhaled, or intra-articular steroids or physiologic endocrine replacement (insulin, levothyroxine, etc.) are permitted. Patients with a history of autoimmune disease that is not currently active require consultation with the protocol principal investigator (PI) and/or Cancer Immunotherapy Trials Network (CITN) Coordinating Center",
            "criterions": [
                {
                    "exact_snippets": "Patients with active underlying autoimmune disease requiring systemic immunosuppressive medication (oral prednisone > 10 mg/day or equivalent)",
                    "criterion": "active underlying autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic immunosuppressive medication"
                        },
                        {
                            "requirement_type": "prednisone dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Topical, inhaled, or intra-articular steroids or physiologic endocrine replacement (insulin, levothyroxine, etc.) are permitted",
                    "criterion": "use of topical, inhaled, or intra-articular steroids or physiologic endocrine replacement",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a history of autoimmune disease that is not currently active require consultation with the protocol principal investigator (PI) and/or Cancer Immunotherapy Trials Network (CITN) Coordinating Center",
                    "criterion": "history of autoimmune disease that is not currently active",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "consultation requirement",
                            "expected_value": "consultation with PI and/or CITN Coordinating Center"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed",
            "criterions": [
                {
                    "exact_snippets": "Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed",
                    "criterion": "bisphosphonate therapy use",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "bone metastasis",
                                "osteoporosis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)",
            "criterions": [
                {
                    "exact_snippets": "No metastases to brain stem, midbrain, pons, medulla, cerebellum",
                    "criterion": "metastases to brain stem, midbrain, pons, medulla, or cerebellum",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No metastases ... within 10 mm of the optic apparatus (optic nerves and chiasm)",
                    "criterion": "metastases within 10 mm of the optic apparatus (optic nerves and chiasm)",
                    "requirements": [
                        {
                            "requirement_type": "distance from optic apparatus",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled",
                    "criterion": "systemic immunosuppressant medication use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "acute"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "low dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)",
            "criterions": [
                {
                    "exact_snippets": "Patients positive for hepatitis C virus (HCV) antibody",
                    "criterion": "hepatitis C virus (HCV) antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "polymerase chain reaction is negative for HCV ribonucleic acid (RNA)",
                    "criterion": "HCV ribonucleic acid (RNA) by polymerase chain reaction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active tuberculosis (TB)",
            "criterions": [
                {
                    "exact_snippets": "Patients with active tuberculosis (TB)",
                    "criterion": "tuberculosis (TB)",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evaluable or measurable disease outside the CNS",
            "criterions": [
                {
                    "exact_snippets": "Evaluable or measurable disease outside the CNS",
                    "criterion": "disease outside the CNS",
                    "requirements": [
                        {
                            "requirement_type": "evaluability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "known primary central nervous system (CNS) malignancy",
                    "criterion": "primary central nervous system (CNS) malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic CNS metastases",
                    "criterion": "symptomatic CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have known additional malignancies other than UBC within 2 years before initiation of study treatment; exceptions include malignancies with a negligible risk of metastasis or death and treated with expected curative outcome (e.g., non-melanomatous skin cancers), or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "known additional malignancies other than UBC within 2 years before initiation of study treatment",
                    "criterion": "additional malignancies (other than UBC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years before initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions include malignancies with a negligible risk of metastasis or death and treated with expected curative outcome (e.g., non-melanomatous skin cancers)",
                    "criterion": "malignancies with negligible risk of metastasis or death and treated with expected curative outcome",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "treatment outcome",
                            "expected_value": "expected curative outcome"
                        }
                    ]
                },
                {
                    "exact_snippets": "localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer",
                    "criterion": "localized prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment intent",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "PSA relapse",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "incidental prostate cancer",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks before initiation of study treatment or at any time during the study",
            "criterions": [
                {
                    "exact_snippets": "Influenza vaccination should be given during influenza season only (approximately October to March)",
                    "criterion": "influenza vaccination timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during influenza season only (approximately October to March)"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must not receive live, attenuated influenza vaccine within 4 weeks before initiation of study treatment",
                    "criterion": "live, attenuated influenza vaccine administration before study",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "administration",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must not receive live, attenuated influenza vaccine ... at any time during the study",
                    "criterion": "live, attenuated influenza vaccine administration during study",
                    "requirements": [
                        {
                            "requirement_type": "administration",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose",
            "criterions": [
                {
                    "exact_snippets": "Minimum of 12 weeks from the first dose of anti-CTLA-4",
                    "criterion": "time since first dose of anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "> 6 weeks from the last dose",
                    "criterion": "time since last dose of anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway -targeting agents",
            "criterions": [
                {
                    "exact_snippets": "received prior treatment with anti-PD-1",
                    "criterion": "prior treatment with anti-PD-1 therapeutic antibody",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received prior treatment with ... anti-PD-L1 therapeutic antibody",
                    "criterion": "prior treatment with anti-PD-L1 therapeutic antibody",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "received prior treatment with ... pathway -targeting agents",
                    "criterion": "prior treatment with pathway-targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier (i.e., have residual toxicities > grade 1); however, the following therapies are allowed:",
            "criterions": [
                {
                    "exact_snippets": "not recovered from adverse events (other than alopecia) ... have residual toxicities > grade 1",
                    "criterion": "adverse events recovery",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "residual_toxicity_grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adverse events (other than alopecia) due to agents administered more than 4 weeks earlier",
                    "criterion": "timing of causative agent administration",
                    "requirements": [
                        {
                            "requirement_type": "time_since_administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "prior allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:",
            "criterions": [
                {
                    "exact_snippets": "Patients with asymptomatic treated CNS metastases may be enrolled",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Prior perioperative chemotherapy is allowed and is not counted as a line of therapy if patient relapsed >= 12 months later and received additional platinum-based chemotherapy for metastatic disease",
            "criterions": [
                {
                    "exact_snippets": "Prior perioperative chemotherapy is allowed",
                    "criterion": "prior perioperative chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is not counted as a line of therapy if patient relapsed >= 12 months later",
                    "criterion": "relapse-free interval after perioperative chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received additional platinum-based chemotherapy for metastatic disease",
                    "criterion": "receipt of additional platinum-based chemotherapy for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "received",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g., infectious) illness",
            "criterions": [
                {
                    "exact_snippets": "Prisoners",
                    "criterion": "prisoner status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g., infectious) illness",
                    "criterion": "compulsory detention for treatment",
                    "requirements": [
                        {
                            "requirement_type": "detention_status",
                            "expected_value": "compulsorily detained"
                        },
                        {
                            "requirement_type": "treatment_reason",
                            "expected_value": [
                                "psychiatric illness",
                                "medical illness"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The use of inhaled corticosteroids, and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
            "criterions": [
                {
                    "exact_snippets": "use of inhaled corticosteroids ... is allowed",
                    "criterion": "inhaled corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use of ... mineralocorticoids (e.g., fludrocortisone) ... is allowed",
                    "criterion": "mineralocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with orthostatic hypotension",
                    "criterion": "orthostatic hypotension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with ... adrenocortical insufficiency",
                    "criterion": "adrenocortical insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hormone-replacement therapy or oral contraceptives",
            "criterions": [
                {
                    "exact_snippets": "Hormone-replacement therapy",
                    "criterion": "hormone-replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "oral contraceptives",
                    "criterion": "oral contraceptives",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted",
            "criterions": [
                {
                    "exact_snippets": "No ongoing requirement for dexamethasone for CNS disease",
                    "criterion": "requirement for dexamethasone for CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "ongoing requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients on a stable dose of anticonvulsants are permitted",
                    "criterion": "anticonvulsant use",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have major surgical procedure, other than for diagnosis, within 28 days before initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study",
            "criterions": [
                {
                    "exact_snippets": "major surgical procedure, other than for diagnosis, within 28 days before initiation of study treatment",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before initiation of study treatment"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "other than for diagnosis"
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for a major surgical procedure during the course of the study",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the course of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study",
            "criterions": [
                {
                    "exact_snippets": "Radiographic demonstration of improvement upon the completion of CNS directed therapy",
                    "criterion": "radiographic improvement after CNS directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "improvement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study",
                    "criterion": "interim CNS disease progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received oral or IV antibiotics within 2 weeks before initiation of study treatment; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible",
            "criterions": [
                {
                    "exact_snippets": "received oral or IV antibiotics within 2 weeks before initiation of study treatment",
                    "criterion": "antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "oral",
                                "IV"
                            ]
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible",
                    "criterion": "prophylactic antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "prophylactic"
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have signs or symptoms of infection within 2 weeks before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "signs or symptoms of infection within 2 weeks before initiation of study treatment",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted",
            "criterions": [
                {
                    "exact_snippets": "history of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... pneumonitis (including drug induced)",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest CT scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence on screening chest CT scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received treatment with any other investigational agent within 4 weeks before initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "received treatment with any other investigational agent within 4 weeks before initiation of study treatment",
                    "criterion": "treatment with investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction (within the last 6 months), or psychiatric illness/social situations that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure (New York Heart Association class III or IV)",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        },
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent myocardial infarction (within the last 6 months)",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (AST and/or ALT=< 5 x ULN for patients with liver involvement)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN",
                    "criterion": "AST and ALT levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and/or ALT =< 5 x ULN for patients with liver involvement",
                    "criterion": "AST and ALT levels in patients with liver involvement",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Patients who have had chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Patients who have had chemotherapy ... within 2 weeks ... before the initiation of study treatment",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have had radiotherapy ... within 2 weeks ... before the initiation of study treatment",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "4 weeks for nitrosoureas or systemic mitomycin C ... before the initiation of study treatment",
                    "criterion": "prior nitrosoureas or systemic mitomycin C",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}